The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).
 
Adrienne Gropper Waks
No Relationships to Disclose
 
William Thomas Barry
Consulting or Advisory Role - ARMO BioSciences
Research Funding - Pfizer (Inst)
 
Evisa Gjini
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Deborah Dillon
No Relationships to Disclose
 
Scott Rodig
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jane E. Brock
No Relationships to Disclose
 
Michele Baltay
Patents, Royalties, Other Intellectual Property - Brainstem Biometrics (I)
 
Jennifer Savoie
No Relationships to Disclose
 
Daniel G. Stover
No Relationships to Disclose
 
Eric P. Winer
Consulting or Advisory Role - Genentech/Roche; Leap Therapeutics; Novartis; Verastem
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Research Funding - Genentech
 
Sara M. Tolaney
Research Funding - Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)